Clinical research

Pre-hospital administration of tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: a sub-analysis of the On-Time 2 trial

EuroIntervention 2010;6:336-342 - DOI10.4244/EIJV6I3A56.

Jorik R. Timmer
Jorik R. Timmer1, MD, PhD; Jurriën ten Berg2, MD, PhD; Antonius A. Heestermans1, MD; Thorsten Dill3, MD, PhD; Jochem W. van Werkum2, MD, PhD; Jan Henk E. Dambrink1, MD, PhD; Harry Suryapranata1, MD, PhD; Jan Paul Ottervanger1, MD, PhD; Christian Hamm3, MD, PhD; Arnoud W.J. van ‘t Hof1, MD, PhD; on behalf of the Ongoing Tirofiban In Myocardial Infarction Evaluation (On - Time) 2 study group
1. Isala Klinieken, Zwolle, The Netherlands; 2. St. Antonius Ziekenhuis, Nieuwegein, The Netherlands; 3. Kerckhoff-Klinik GmbH, Bad Nauheim, Germany

Aims: Glycoprotein IIb/IIIa blocking agents seem to improve percutaneous coronary intervention (PCI) results in patients with ST-elevation myocardial infarction (STEMI). We aimed to compare

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

myocardial infarctionpcidiabetesglycoprotein iib/iiia blockers
Read next article
The coronary Stent-On-A-Wire (SOAW)

Latest news